23 March 2026
QV Bioelectronics Attends LSI USA 2026 in Dana Point
QV Bioelectronics was pleased to attend LSI USA 2026 in Dana Point, California, one of the leading global gatherings for emerging medtech companies, investors, and…
17 March 2026
Leadership Update
QV Bioelectronics is pleased to announce a leadership transition as the company enters its next phase of growth and clinical development. Carl Daintree has assumed…
21 January 2026
QV Bioelectronics secures £4.5m to advance implantable brain cancer therapy into first-in-human studies
QV Bioelectronics has secured £4.5m in investment and grant funding to support the next phase of development of GRACE, its world-first fully implantable electric field…
7 May 2025
Backing Secured to Prepare First Trial of Implanted Electric Field Therapy
QV Bioelectronics, developer of a first-in-class implanted Electric Field Therapy (EFT) device for brain tumours, has been awarded a £1.26 million grant under the highly…
12 March 2025
Carl Daintree Joins QV Bioelectronics as COO
Welcoming Carl to QV Bioelectronics! We’re excited to welcome Carl Daintree to the QV Bioelectronics team as the new COO! Carl has deep cross-functional experience,…
9 September 2024
QV Bioelectronics Delivers Breakthrough Pre-Clinical Safety and Efficacy Results for Electric Field Therapy in the treatment of GBM
30th August 2024, Cheshire, UK QV Bioelectronics, the creator of the world’s first implantable Electric Field Therapy (EFT) device for the treatment of brain tumours,…
Interested in Receiving our Press Releases?